Thursday's rally was sparked by news that Moderna's Covid-19 vaccine candidate is moving to Phase II testing.
After CVS released quarterly earnings and the CEO's appearance on 'Mad Money,' let's look at the charts for this health and pharmacy retailer.
I see no reason to put much money into longer-term positions right now, but here are some of my biggest positions.
Use available weakness to go long or add to longs.
A lifting on the moratorium on elective procedures could be a big win for ABBV.
CVS Health states that the chain has kept its stores open as an 'essential' retailer through this pandemic.
Merger activity is picking up this week in the biotechnology sector and these four promising companies would be good buyout candidates.
PFE is collaborating with German drugmaker BioNTech in the effort to find a well tolerated, effective vaccine.
The charts of CVS are in good shape, so expect renewed strength in the weeks ahead.
This biotech is on the front lines of oncology treatments.